1. 8PSAFETY OF IMPRIME PGG, A NOVEL INNATE IMMUNE MODULATOR, IN ADULTS WITH STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC). (November 2014) Authors: Thomas, M.; Schneller, F.; Sadjadian, P.; Hao, Z.; Mattson, P.; Lowe, J.; Huhn, R.; Braun, A.; Taitt, C. Journal: Annals of oncology Issue: Volume 25(2014)Supplement 6 Page Start: vi3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anti-beta glucan antibodies represent a mechanism-based biomarker to select patients responsive to the novel immunotherapeutic, Imprime PGG. (December 2016) Authors: Bose, N.; Ottoson, N.; Harrison, B.; Chan, A.; Bykowski Jonas, A.; Qiu, X.; Ma, M.; Huhn, R.; Lowe, J.; Walsh, R.; Gorden, K.; Leonardo, S.; Ertelt, K.; Danielson, M.; Michel, K.; Patchen, M.; Uhlik, M.; Iglesias, J.; Graff, J. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S106 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗